PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18281123-9 2008 Treatment with SP600125 and transfection with DN-JNK blocked Bcl-xL phosphorylation, suggesting that JNK plays an important role in sulindac/ATO-induced Bcl-xL phosphorylation. Sulindac 132-140 BCL2 like 1 Homo sapiens 61-67 18281123-0 2008 A combination of sulindac and arsenic trioxide synergistically induces apoptosis in human lung cancer H1299 cells via c-Jun NH2-terminal kinase-dependent Bcl-xL phosphorylation. Sulindac 17-25 BCL2 like 1 Homo sapiens 154-160 18281123-6 2008 Interestingly, a slower migrating Bcl-xL band was observed on immunoblots after treatment of cells with sulindac/ATO. Sulindac 104-112 BCL2 like 1 Homo sapiens 34-40 18281123-9 2008 Treatment with SP600125 and transfection with DN-JNK blocked Bcl-xL phosphorylation, suggesting that JNK plays an important role in sulindac/ATO-induced Bcl-xL phosphorylation. Sulindac 132-140 BCL2 like 1 Homo sapiens 153-159 18281123-10 2008 In conclusion, in H1299 human NSCLC cells, sulindac and ATO synergistically induce a high degree of apoptosis, which is mediated by the ROS-dependent JNK activation pathway via Bcl-xL phosphorylation. Sulindac 43-51 BCL2 like 1 Homo sapiens 177-183 14576498-13 2003 The expression of several cell cycle (p21, p27, cyclin D1) and apoptotic (survivin, Bcl-xL) regulatory proteins was altered after U0126 and/or sulindac treatment. Sulindac 143-151 BCL2 like 1 Homo sapiens 84-90 11912124-0 2002 Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L). Sulindac 91-99 BCL2 like 1 Homo sapiens 123-131